BioCentury | Jul 21, 2020
Emerging Company Profile
Hybrid CDMO-gene therapy developer Forge launches with $40M
...company work. The Perceptive Xontogeny Venture (PXV) fund led the company’s series A round, with Drive Capital...
...of employees: Undisclosed Funds raised: At least $40 million Investors: Perceptive Xontogeny Venture (PXV) fund, Drive Capital...
...of employees: Undisclosed Funds raised: At least $40 million Investors: Perceptive Xontogeny Venture (PXV) fund, Drive Capital...
